This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lipidor (L7R) Stock Overview

A pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. More details

L7R fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 1.2% per year over past 5 years

Makes less than USD$1m in revenue (SEK6M)

+ 1 more risk

L7R Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,562 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

474,562 investors already sharing narratives

View all narratives

Lipidor AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lipidor
Historical stock prices
Current Share Price	€0.0001
52 Week High	€0.008
52 Week Low	€0.0001
Beta	0.56
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-98.73%

Recent updates

Shareholder Returns

	L7R	DE Pharmaceuticals	DE Market
7D	-98.7%	4.0%	1.2%
1Y	n/a	43.3%	0.7%

Return vs Industry: Insufficient data to determine how L7R performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how L7R performed against the German Market.

Price Volatility

Is L7R's price volatile compared to industry and market?
L7R volatility
L7R Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: L7R's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine L7R's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	4	Ola Holmlund	lipidor.se

Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.

Lipidor AB (publ) Fundamentals Summary

How do Lipidor's earnings and revenue compare to its market cap?
L7R fundamental statistics
Market cap	€81.34k
Earnings (TTM)	-€1.26m
Revenue (TTM)	€531.84k

0.2x

P/S Ratio

-0.1x

P/E Ratio

Is L7R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
L7R income statement (TTM)
Revenue	SEK 5.85m
Cost of Revenue	SEK 10.73m
Gross Profit	-SEK 4.89m
Other Expenses	SEK 8.92m
Earnings	-SEK 13.81m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 28, 2025

Earnings per share (EPS)	-0.017
Gross Margin	-83.63%
Net Profit Margin	-236.20%
Debt/Equity Ratio	0%

How did L7R perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/08 20:01
End of Day Share Price	2025/06/05 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipidor AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Lipidor AB (publ)BST:L7R Stock Report